Literature DB >> 21681778

RhoGDIα suppresses growth and survival of prostate cancer cells.

Yezi Zhu1, Ramakumar Tummala, Chengfei Liu, Nagalakshmi Nadiminty, Wei Lou, Christopher P Evans, Qinghua Zhou, Allen C Gao.   

Abstract

BACKGROUND: Treatment for primary prostate cancer (CaP) is the withdrawal of androgens. However, CaP eventually progresses to grow in a castration-resistant state. The mechanisms involved in the development and progression of castration-resistant prostate cancer (CRPC) remain unknown. We have previously generated LNCaP-IL6+ cells by treating LNCaP cells chronically with interleukin-6 (IL-6), which have acquired the ability to grow in androgen-deprived conditions.
METHODS: We compared the protein expression profile of LNCaP and LNCaP-IL6+ cells using two-dimensional gel electrophoresis. The gels were then silver stained in order to visualize proteins and the differentially expressed spots were identified and characterized by micro sequencing using MALDI-PMF mass spectrometry.
RESULTS: In this study, we have identified RhoGDIα (GDIα) as a suppressor of CaP growth. Expression of GDIα was reduced in LNCaP-IL6+ cells and was down-regulated in more aggressive CaP cells compared to LNCaP cells. Over expression of GDIα inhibited the growth of CaP cells and caused LNCaP-IL6+ cells reversal to androgen-sensitive state, while down-regulation of GDIα enhanced growth of androgen-sensitive LNCaP CaP cells in androgen-deprived conditions. In addition, GDIα suppressed the tumorigenic ability of prostate tumor xenografts in vivo.
CONCLUSIONS: These results demonstrate that loss of GDIα expression promotes the development and progression of prostate cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681778      PMCID: PMC3961824          DOI: 10.1002/pros.21441

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

1.  STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .

Authors:  M T Spiotto; T D Chung
Journal:  Prostate       Date:  2000-02-15       Impact factor: 4.104

2.  Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

Authors:  P D Deeble; D J Murphy; S J Parsons; M E Cox
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.

Authors:  A Hobisch; H Rogatsch; A Hittmair; D Fuchs; G Bartsch; H Klocker; G Bartsch; Z Culig
Journal:  J Pathol       Date:  2000-07       Impact factor: 7.996

4.  Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Authors:  Ines Barone; Lauren Brusco; Guowei Gu; Jennifer Selever; Amanda Beyer; Kyle R Covington; Anna Tsimelzon; Tao Wang; Susan G Hilsenbeck; Gary C Chamness; Sebastiano Andò; Suzanne A W Fuqua
Journal:  J Natl Cancer Inst       Date:  2011-03-29       Impact factor: 13.506

5.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.

Authors:  A Hobisch; R Ramoner; D Fuchs; S Godoy-Tundidor; G Bartsch; H Klocker; Z Culig
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

6.  The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines.

Authors:  M J Seraj; M A Harding; J J Gildea; D R Welch; D Theodorescu
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

7.  Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility.

Authors:  K Takaishi; A Kikuchi; S Kuroda; K Kotani; T Sasaki; Y Takai
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

8.  Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Authors:  P C Smith; E T Keller
Journal:  Prostate       Date:  2001-06-15       Impact factor: 4.104

9.  Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia.

Authors:  M J Siegsmund; H Yamazaki; I Pastan
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

10.  Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.

Authors:  C B Siegall; G Schwab; R P Nordan; D J FitzGerald; I Pastan
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 13.312

View more
  9 in total

1.  Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Authors:  Yezi Zhu; Chengfei Liu; Cameron Armstrong; Wei Lou; Amandeep Sandher; Allen C Gao
Journal:  Clin Cancer Res       Date:  2015-05-20       Impact factor: 12.531

Review 2.  Emerging Proteins in CRPC: Functional Roles and Clinical Implications.

Authors:  Piaoping Kong; Lingyu Zhang; Zhengliang Zhang; Kangle Feng; Yiwen Sang; Xiuzhi Duan; Chunhua Liu; Tao Sun; Zhihua Tao; Weiwei Liu
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

3.  RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.

Authors:  Yezi Zhu; Chengfei Liu; Ramakumar Tummala; Nagalakshmi Nadiminty; Wei Lou; Allen C Gao
Journal:  Prostate       Date:  2013-08-06       Impact factor: 4.104

4.  Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.

Authors:  Laurent Chouchana; Ana Aurora Fernández-Ramos; Florent Dumont; Catherine Marchetti; Irène Ceballos-Picot; Philippe Beaune; David Gurwitz; Marie-Anne Loriot
Journal:  Genome Med       Date:  2015-04-18       Impact factor: 11.117

5.  RhoGDIα suppresses self-renewal and tumorigenesis of glioma stem cells.

Authors:  Fan Wu; Peishan Hu; Dengke Li; Yan Hu; Yingjiao Qi; Bin Yin; Tao Jiang; Jiangang Yuan; Wei Han; Xiaozhong Peng
Journal:  Oncotarget       Date:  2016-09-20

6.  Rho GDP-dissociation inhibitor α is a potential prognostic biomarker and controls telomere regulation in colorectal cancer.

Authors:  Dandan Huang; Weisi Lu; Shaomin Zou; Huaiming Wang; Yuanling Jiang; Xiya Zhang; Pengqing Li; Zhou Songyang; Lei Wang; Jianping Wang; Junjiu Huang; Lekun Fang
Journal:  Cancer Sci       Date:  2017-05-31       Impact factor: 6.716

7.  Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151.

Authors:  Takeshi Chiyomaru; Soichiro Yamamura; Mohd Saif Zaman; Shahana Majid; Guoren Deng; Varahram Shahryari; Sharanjot Saini; Hiroshi Hirata; Koji Ueno; Inik Chang; Yuichiro Tanaka; Z Laura Tabatabai; Hideki Enokida; Masayuki Nakagawa; Rajvir Dahiya
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

8.  Interplay between PCBP2 and miRNA modulates ARHGDIA expression and function in glioma migration and invasion.

Authors:  Xihua Lin; Bin Yang; Wei Liu; Xiaochao Tan; Fan Wu; Peishan Hu; Tao Jiang; Zhaoshi Bao; Jiangang Yuan; Boqin Qiang; Xiaozhong Peng; Wei Han
Journal:  Oncotarget       Date:  2016-04-12

9.  Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.

Authors:  Yabing Chen; Chun Pan; Xiaotong Wang; Dihui Xu; Yuhan Ma; Jianhang Hu; Peilin Chen; Zou Xiang; Qiu Rao; Xiaodong Han
Journal:  Theranostics       Date:  2021-06-11       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.